USFDA inspected Supriya Lifescience's Maharashtra facility from Feb 2-6, 2026, issuing one minor observation.
Company received VAI (Voluntary Action Indicated) status in EIR, indicating successful inspection completion.
Disclosure made under SEBI LODR Regulation 30 regarding compliance update.